Advanced Practice

Nephrotoxicity among young patients with cancer: Not only an acute problem

HemOnc Today, August 25, 2019
Lisa Triche, DNP, RN, CPNP
Balancing long-term risks and benefits of potentially toxic therapies, while achieving a cure, remains a delicate challenge in cancer treatment…
Pharmacology Consult

Immunotherapy effective for many patients ineligible for registration trials, but caution necessary

HemOnc Today, August 25, 2019
Jai N. Patel, PharmD, BCOP
One of the hot topics at this year’s ASCO Annual Meeting was broadening eligibility criteria to increase clinical trial access and enrollment…

Trial to assess CRISPR genome editing platform in non-small cell lung cancer

August 20, 2019
The Gene Editing Institute of the Helen F. Graham Cancer Center and Research Institute at Christiana Care has launched a clinical development program…

‘Smarter and stronger’ T cells offer hope for more effective, less toxic cancer therapy

August 18, 2019
Editor’s note: This is the first in a series of articles that spotlight research efforts supported through Cancer Research Institute’s…

New targets, treatment strategies create ‘exciting time’ in triple-negative breast cancer

August 17, 2019
Although breast cancer mortality has declined by 40% over the past several decades, more than 40,000 women will die of the disease this year…

Noninvasive prenatal test shows potential for sickle cell disease diagnosis

August 15, 2019
A noninvasive prenatal test developed by researchers in the United Kingdom appeared effective for diagnosis of sickle cell disease among a small…
Molecular Oncology

Ovarian cancer: Is this the beginning of the end?

HemOnc Today, August 10, 2019
Michael J. Birrer, MD, PhD
There will be 22,530 new cases of ovarian cancer in the United States this year. Although tumors often present at an advanced stage, it remains one…

Patient access to new cancer treatments — an uncertain and fragile process

HemOnc Today, August 10, 2019
John Sweetenham, MD
As Tom Brokaw eloquently stated, uncertainty is at the heart of the cancer experience for our patients. It impacts many aspects of their lives, from…
Cover Story

BCG: a real-world example of health care rationing

HemOnc Today, August 10, 2019
Bacillus Calmette-Guérin, or BCG, is highly effective at treating and preventing recurrence of early-stage bladder cancer. BCG is a strain of…

Are there feasible alternatives to BCG for the effective treatment of bladder cancer?

HemOnc Today, August 10, 2019
POINT The BCG shortage has caused significant concern among both patients and providers as they consider their options for the treatment of…